Wave Life Sciences (WVE) Operating Leases (2019 - 2026)

Wave Life Sciences' Operating Leases history runs 8 years deep, the most recent figure standing at $7.4 million for Q1 2026.

• Quarterly Operating Leases fell 52.99% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.4 million (down 52.99% YoY) and the FY2025 annual result came in at $9.4 million, down 47.06% from the prior year.
• Operating Leases was $7.4 million for Q1 2026 at Wave Life Sciences, down from $9.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $33.7 million in Q3 2022 and bottomed at $7.4 million in Q1 2026.
• A 5-year average of $20.8 million and a median of $21.7 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2023 — Operating Leases jumped 140.62% — and 2026, when it tumbled 52.99%.
• Wave Life Sciences' Operating Leases stood at $32.1 million in 2022, then dropped by 20.9% to $25.4 million in 2023, then tumbled by 30.07% to $17.8 million in 2024, then tumbled by 47.06% to $9.4 million in 2025, then declined by 21.46% to $7.4 million in 2026.
• Business Quant data shows WVE's Operating Leases at $7.4 million in Q1 2026, $9.4 million in Q4 2025, and $11.4 million in Q3 2025.